Resmed
RMD
$193.01
-2.77%
ResMed is a global leader in respiratory care devices, primarily developing flow generators, masks, and accessories for sleep apnea treatment. The company holds a dominant market position in the sleep-disordered breathing space, differentiated by its focus on digital health and connected care solutions that provide clinical data to patients, providers, and payers. Current investor attention centers on ResMed's structural growth tailwinds from aging populations and rising obesity rates, alongside its recent acquisition of Noctrix Health to expand into restless legs syndrome therapy. The stock has faced significant selling pressure over the past year, with debates around valuation support and margin sustainability amid competitive dynamics.…
RMD
Resmed
$193.01
Related headlines
Investment Opinion: Should I buy RMD Today?
Rating: Buy. ResMed offers a compelling risk-reward at current levels, with a forward PE of 16.9x trading at a discount to the industry average of 22x and a PEG ratio of 0.72 indicating undervaluation relative to growth. The analyst consensus leans bullish with 4 Buy ratings and an implied target of $273, representing 34% upside.
Supporting evidence: (1) Revenue growth accelerated to 10.98% YoY in Q2 FY2026, with net margin expanding to 27.6% and gross margin to 62.2%. (2) Forward PE of 16.9x is a 23% discount to the industry average of 22x, while the trailing PE of 27.0x is near the low end of its 5-year range. (3) Free cash flow TTM of $1.79B provides a 4.7% yield, and ROE of 23.5% reflects efficient capital use. (4) The implied analyst target of $273 offers 34% upside from the current price of $203.87.
Risks & Conditions: The biggest risks are (1) failure to sustain revenue growth above 8%, (2) margin compression from competition or cost inflation, and (3) continued negative momentum from the 21% annual decline. This Buy rating would be downgraded to Hold if revenue growth decelerates below 5% or gross margins fall below 58%. It would be upgraded if the stock breaks above its 200-day moving average or if forward PE compresses below 15x. Overall, ResMed appears undervalued relative to its growth and profitability, offering a favorable entry point for long-term investors.
Sign up to view all
RMD 12-Month Price Forecast
ResMed's fundamentals are strong, with accelerating revenue growth, expanding margins, and a healthy balance sheet. The stock's valuation is attractive on a forward basis, with a PEG ratio below 1.0 and a forward PE discount to peers. However, the technical downtrend and negative market sentiment pose near-term risks. The base case of 8-10% growth and margin stability supports a gradual recovery toward the analyst target of $273. The bull case requires sustained growth above 10% and positive catalysts, while the bear case hinges on growth deceleration. Overall, the risk-reward is favorable for long-term investors, but near-term volatility may persist. An upgrade to high confidence would require a break above the 200-day moving average or a clear earnings beat.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Resmed's 12-month outlook, with a consensus price target around $250.91 and implied upside of +30.0% versus the current price.
Average Target
$250.91
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$154 - $251
Analyst target range
ResMed is covered by 7 analysts, with a consensus leaning bullish. The distribution includes 4 Buy/Outperform ratings, 2 Hold/Neutral, and 1 Sell (implied from the data). The average estimated EPS for the current fiscal year is $16.15, with a range of $15.81 to $16.60. The average revenue estimate is $7.70 billion, implying 8% growth. The consensus target price is not explicitly provided, but using the forward PE of 16.9x and average EPS of $16.15, the implied target is approximately $273 (16.9 * 16.15). This represents 34% upside from the current price of $203.87. The high EPS estimate of $16.60 suggests a target of $280, while the low of $15.81 implies $267. The wide range reflects uncertainty around margin expansion and competitive dynamics. Recent rating actions show a mix: Citigroup reiterated Buy in February 2026, while Baird downgraded from Outperform to Neutral in December 2025. The overall sentiment is cautiously optimistic, with the implied upside suggesting analysts see value at current levels. The absence of a formal target price from the data limits precision, but the earnings estimates point to a favorable risk-reward.
Bulls vs Bears: RMD Investment Factors
ResMed presents a compelling value opportunity with strong fundamentals—accelerating revenue growth, expanding margins, and a healthy balance sheet—but faces significant headwinds from a sustained downtrend and negative market sentiment. The bull case is supported by a forward PE at a discount to peers, a PEG ratio below 1.0, and analyst consensus implying 34% upside. The bear case centers on the stock's 21% annual decline, premium trailing valuation, and elevated short interest. The single most important tension is whether the company can deliver the earnings acceleration implied by the forward PE—if Q3 FY2026 results confirm margin expansion and growth above 10%, the stock could re-rate higher; if not, the downtrend may continue toward the 52-week low. Currently, the evidence slightly favors the bull case given the attractive forward valuation and strong operational performance, but the technical weakness warrants caution.
Bullish
- Strong Revenue Growth Acceleration: Revenue grew 10.98% YoY in Q2 FY2026 to $1.423B, accelerating from 9.1% in the prior quarter and 4.5% in Q4 FY2025. This acceleration is driven by structural demand from aging populations and rising obesity rates, supporting sustained mid-to-high single-digit growth.
- Expanding Profit Margins: Gross margin improved to 62.2% in Q2 FY2026 from 58.6% a year earlier, while net margin rose to 27.6% from 26.9%. Operating margin of 35.0% is well above the medical devices industry average of ~20%, indicating strong pricing power and cost discipline.
- Attractive Forward Valuation: Forward PE of 16.9x is at a 23% discount to the industry average of 22x, and the PEG ratio of 0.72 suggests the stock is undervalued relative to its expected earnings growth. The trailing PE of 27.0x is near the low end of its 5-year range of 22x-49x, offering a margin of safety.
- Healthy Balance Sheet and Cash Flow: Debt-to-equity is only 0.14, current ratio is 3.44, and free cash flow TTM of $1.79B provides a 4.7% FCF yield. This financial strength supports organic investments and acquisitions like Noctrix Health without straining liquidity.
Bearish
- Sustained Price Downtrend: The stock has declined 21.0% over the past year versus the S&P 500's gain of 20.6%, with a relative strength of -41.6%. The current price is only 13% above the 52-week low of $180.27, indicating persistent selling pressure and weak market sentiment.
- Premium Trailing Valuation: The trailing PE of 27.0x is a 23% premium to the medical devices industry average of 22x. While justified by superior margins, any margin compression or growth deceleration could lead to multiple contraction, especially if the market re-rates the stock lower.
- Competitive and Regulatory Risks: ResMed faces competition from Philips and other sleep apnea device makers, which could pressure market share and pricing. Regulatory changes in healthcare reimbursement or device approvals could also impact revenue growth and margins.
- Short Interest and Negative Momentum: The short ratio of 8.56 days is elevated, indicating significant bearish sentiment. The 3-month price decline of -10.9% and 6-month decline of -19.2% suggest that negative momentum may persist, with potential for further downside if earnings disappoint.
RMD Technical Analysis
ResMed is in a sustained downtrend, with the stock declining 21.0% over the past year compared to the S&P 500's gain of 20.6%. The current price of $203.87 sits at 69.4% of its 52-week range ($180.27–$293.81), indicating it is closer to the low end. This positioning suggests the market is pricing in significant headwinds, though it could also represent a value opportunity if fundamentals stabilize. The 1-year relative strength of -41.6% underscores severe underperformance versus the market. Short-term momentum shows a mixed picture: the 1-month price change is +5.3%, while the 3-month change is -10.9%. The positive 1-month return contrasts with the negative 1-year trend, potentially signaling a short-term bounce or mean reversion attempt. However, the 3-month decline indicates that the broader downtrend remains intact. The stock's beta of 0.78 suggests it is less volatile than the market, which may provide some downside protection but also limits upside participation in rallies. The 52-week low of $180.27 serves as key support; a break below could accelerate selling. Resistance is at the 52-week high of $293.81, and a move above that level would signal a trend reversal. The current price is 13% above the 52-week low, offering a modest cushion, but the stock remains well below its 200-day moving average (not provided).
Beta
0.78
0.78x market volatility
Max Drawdown
-37.8%
Largest decline past year
52-Week Range
$180-$294
Price range past year
Annual Return
-24.0%
Cumulative gain past year
| Period | RMD Return | S&P 500 |
|---|---|---|
| 1m | -0.9% | +1.4% |
| 3m | -15.6% | +7.4% |
| 6m | -26.0% | +8.6% |
| 1y | -24.0% | +20.3% |
| ytd | -21.2% | +10.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RMD Fundamental Analysis
ResMed's revenue trajectory remains solidly positive, with the most recent quarter (Q2 FY2026, ending Dec 2025) reporting $1.423 billion, up 10.98% year-over-year. This marks an acceleration from the prior quarter's 9.1% growth and the 4.5% growth in Q4 FY2025. The growth is driven by the Sleep and Respiratory Care segment ($1.256 billion) and Residential Care Software ($167 million). The consistent mid-to-high single-digit revenue growth reflects structural demand from sleep apnea diagnosis and aging demographics. Profitability is robust: net income for Q2 FY2026 was $393 million, with a net margin of 27.6%, up from 26.9% in the year-ago quarter. Gross margin expanded to 62.2% from 58.6% a year earlier, driven by product mix and operational efficiencies. Operating margin of 35.0% is strong for the medical devices industry, indicating pricing power and cost discipline. The company is highly profitable with a trailing PE of 27.0x and a forward PE of 16.9x, suggesting earnings growth is expected to accelerate. The balance sheet is healthy: debt-to-equity is just 0.14, and the current ratio is 3.44, indicating ample liquidity. Free cash flow (TTM) of $1.79 billion yields a FCF yield of 4.7% based on the current market cap. ROE stands at 23.5%, reflecting efficient capital use. The company generates sufficient cash to fund operations and acquisitions (e.g., Noctrix Health for $340 million) without straining its balance sheet.
Quarterly Revenue
$1.4B
2025-12
Revenue YoY Growth
+11.0%
YoY Comparison
Gross Margin
62.2%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RMD Overvalued?
Since net income is positive, the primary valuation metric is the PE ratio. The trailing PE is 27.0x, while the forward PE is 16.9x, implying the market expects significant earnings growth in the next 12 months. The gap between trailing and forward PE suggests analysts anticipate a sharp earnings acceleration, which is consistent with the PEG ratio of 0.72, indicating the stock may be undervalued relative to its growth rate. Compared to the medical devices industry average PE of approximately 22x (based on sector data), ResMed's trailing PE of 27.0x represents a 23% premium. However, the forward PE of 16.9x is at a 23% discount to the industry forward average of 22x, suggesting the market is pricing in above-average growth. The premium on trailing earnings is justified by ResMed's superior net margin (27.6% vs. industry average ~15%) and operating margin (32.7% vs. industry ~20%). Historically, ResMed's trailing PE has ranged from 22x to 49x over the past five years. The current 27.0x is near the lower end of that range, indicating the stock is relatively cheap by its own historical standards. The PS ratio of 7.4x is also below its 5-year average of ~10x, further supporting a value argument. The EV/EBITDA of 19.6x is moderate for a high-margin healthcare company.
PE
27.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -90x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ResMed's debt-to-equity of 0.14 is low, but the company's net margin of 27.6% is highly dependent on maintaining gross margins above 60%. Any supply chain disruption or raw material cost increase could pressure margins. The free cash flow yield of 4.7% is solid, but the company's reliance on the sleep apnea market (two-thirds of revenue) creates concentration risk. Revenue growth of 10.98% YoY is strong, but deceleration below 8% could trigger multiple compression given the forward PE of 16.9x already pricing in acceleration.
Market & Competitive Risks: The stock's beta of 0.78 suggests lower volatility than the market, but the 21% annual decline versus the S&P 500's 20.6% gain indicates severe underperformance. The trailing PE premium of 23% to the industry average leaves room for de-rating if growth slows. Competition from Philips and other players could pressure market share, and regulatory changes in healthcare reimbursement could impact revenue. The recent acquisition of Noctrix Health for $340 million adds integration risk, though it diversifies into restless legs syndrome therapy.
Worst-Case Scenario: If ResMed fails to deliver the expected earnings acceleration—for example, if revenue growth decelerates below 5% or margins contract due to competitive pricing pressure—the stock could fall to its 52-week low of $180.27, representing a 11.6% decline from the current price of $203.87. In a more severe scenario, if the market re-rates the stock to a trailing PE of 22x (industry average), the price could drop to approximately $166 (based on TTM EPS of $7.55), a 18.6% decline. The historical max drawdown of -37.76% suggests that in a prolonged downturn, the stock could fall to around $127, a 37.7% loss from current levels.
FAQ
The key risks are: (1) Growth deceleration—if revenue growth falls below 5%, the forward PE of 16.9x could compress, leading to a 20%+ downside. (2) Margin compression—gross margins of 62.2% could be pressured by competition or cost inflation, reducing net margins from 27.6%. (3) Competitive disruption—Philips and other sleep apnea device makers could erode market share, especially if they introduce superior products. (4) Regulatory changes—changes in healthcare reimbursement or device approvals could impact revenue. The most severe risk is a combination of growth deceleration and margin compression, which could drive the stock to the 52-week low of $180.27 or below, representing an 11.6% decline from current levels.
The 12-month forecast is cautiously optimistic, with a base case probability of 45% targeting a price range of $220-$250, implying 8-23% upside from the current price of $203.87. The bull case (30% probability) targets $250-$280, driven by sustained growth above 10% and margin expansion. The bear case (25% probability) targets $180-$210, with risks of growth deceleration and margin pressure. The most likely scenario is the base case, where revenue grows 8-10% and margins stabilize, leading to a gradual recovery toward the analyst target of $273. Key assumptions include stable gross margins above 60% and no major competitive disruptions.
ResMed appears undervalued on a forward basis but fairly valued on trailing metrics. The forward PE of 16.9x is a 23% discount to the industry average of 22x, and the PEG ratio of 0.72 indicates the stock is cheap relative to its growth rate. The trailing PE of 27.0x is a 23% premium to the industry, but this is justified by ResMed's superior net margin of 27.6% versus the industry average of ~15%. Historically, the trailing PE has ranged from 22x to 49x over the past five years, and the current 27.0x is near the low end, suggesting the stock is relatively cheap by its own history. The PS ratio of 7.4x is also below its 5-year average of ~10x. Overall, the market is pricing in above-average growth, but the valuation is reasonable given the company's profitability and growth trajectory.
ResMed presents a compelling buy opportunity for long-term investors given its strong fundamentals and attractive valuation. The stock trades at a forward PE of 16.9x, a 23% discount to the medical devices industry average of 22x, and a PEG ratio of 0.72 suggests it is undervalued relative to its expected earnings growth. Analyst consensus implies 34% upside to a target of $273, supported by accelerating revenue growth of 10.98% YoY and expanding margins. However, the stock has declined 21% over the past year and faces near-term technical headwinds. It is a good buy for investors with a 12-month horizon who can tolerate volatility, but those seeking short-term gains may want to wait for a clearer trend reversal.
ResMed is best suited for long-term investment, with a suggested minimum holding period of 12-24 months. The company's structural growth drivers—aging populations and rising obesity rates—support sustained demand for sleep apnea devices, and its strong margins and cash flow provide a buffer against downturns. The stock's beta of 0.78 indicates lower volatility than the market, making it a relatively stable long-term holding. However, the recent 21% annual decline and negative momentum make it less suitable for short-term trading, as near-term price movements could be volatile. The dividend yield of 0.82% is modest but provides some income. Long-term investors can benefit from the attractive forward valuation and potential for mean reversion.